A novel strategy to suppress prostate cancer growth
The researchers took a close look into what drives the growth of advanced tumors that have become resistant to standard castration therapy.
Read MoreThe researchers took a close look into what drives the growth of advanced tumors that have become resistant to standard castration therapy.
Read MoreInhibiting MAPK4 simultaneously inactivated both androgen receptor and AKT and stopped cancer growth in animal models.
Read MoreGenetic factors can explain, at last in part, the higher incidence of prostate cancer among African American men compared with men of other ethnic groups.
Read MoreDuring the month of September, Baylor College of Medicine will be partnering with the Blue Cure Foundation for its annual prostate cancer awareness campaign, Light
Read MoreAdvanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the
Read MoreNearly 200 thousand men are diagnosed with prostate cancer every year. Most of the deaths associated with prostate cancer occur in advanced stages of the
Read MoreSeptember officially kicks off National Prostate Cancer Awareness Month, and in a show of support for increased awareness, education, research and clinical advances, the Baylor
Read MoreBy Ruth SoRelle, M.P.H. A steroid receptor coactivator (SRC-2) drives the metabolic mechanism that allows prostate cancer not only to grow but also to spread
Read MoreBy Ruth SoRelle, M.P.H. Treating advanced prostate cancer with drugs that block androgens or male hormones can result in resistance to the drugs, and is
Read MoreThis study has advanced our understanding of the molecular mechanisms underlying the tumor-promoting activity of MAPK4.
Read More